Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
Descriptor ID |
D047428
|
MeSH Number(s) |
D27.505.519.389.755
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 2 | 2 |
1995 | 1 | 1 | 2 |
1997 | 0 | 1 | 1 |
1999 | 1 | 0 | 1 |
2000 | 2 | 0 | 2 |
2001 | 0 | 2 | 2 |
2002 | 0 | 1 | 1 |
2003 | 0 | 2 | 2 |
2004 | 4 | 9 | 13 |
2005 | 9 | 13 | 22 |
2006 | 42 | 22 | 64 |
2007 | 44 | 33 | 77 |
2008 | 42 | 34 | 76 |
2009 | 60 | 30 | 90 |
2010 | 72 | 37 | 109 |
2011 | 80 | 42 | 122 |
2012 | 78 | 54 | 132 |
2013 | 91 | 46 | 137 |
2014 | 85 | 45 | 130 |
2015 | 95 | 46 | 141 |
2016 | 81 | 42 | 123 |
2017 | 93 | 54 | 147 |
2018 | 81 | 36 | 117 |
2019 | 77 | 51 | 128 |
2020 | 60 | 43 | 103 |
2021 | 67 | 47 | 114 |
2022 | 12 | 81 | 93 |
2023 | 7 | 86 | 93 |
2024 | 1 | 10 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study. Mol Cancer. 2024 03 26; 23(1):64.
-
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC. Cancer Res Commun. 2024 Mar 14; 4(3):786-795.
-
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations. Lung Cancer. 2024 Apr; 190:107512.
-
Targeting ATR in patients with cancer. Nat Rev Clin Oncol. 2024 Apr; 21(4):278-293.
-
Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2024 Mar; 34(3):336-346.
-
Degradation trumps mutations in cancer. Science. 2024 Feb 02; 383(6682):480-481.
-
Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors. J Natl Compr Canc Netw. 2024 02; 22(1).
-
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia. 2024 Mar; 38(3):475-481.
-
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 2024 Mar; 34(3):347-359.
-
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancers. Ann Surg Oncol. 2024 Apr; 31(4):2202-2203.